Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 574

1.

Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.

Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, Lüscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, Wijns W, Zeller T, Schmieder RE.

Eur Heart J. 2015 May 18. pii: ehv192. [Epub ahead of print] Review. No abstract available.

PMID:
25990344
2.

Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension.

Ott C, Schmid A, Toennes SW, Ditting T, Veelken R, Uder M, Schmieder RE.

EuroIntervention. 2015 May 19;11(1):110-6. doi: 10.4244/EIJV11I1A19.

3.

Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry.

Schmieder RE, Gitt AK, Koch C, Bramlage P, Ouarrak T, Tschöpe D; DIALOGUE study group.

BMC Endocr Disord. 2015 May 2;15(1):23. doi: 10.1186/s12902-015-0020-7.

4.

Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension.

Ott C, Mahfoud F, Schmid A, Toennes SW, Ewen S, Ditting T, Veelken R, Ukena C, Uder M, Böhm M, Schmieder RE.

J Hypertens. 2015 Jun;33(6):1261-6. doi: 10.1097/HJH.0000000000000556.

PMID:
25923731
5.

Retinal microperfusion after renal denervation in treatment-resistant hypertensive patients.

Ott C, Harazny JM, Schmid A, Ditting T, Veelken R, Bladowski M, Michelson G, Uder M, Schmieder RE.

Clin Res Cardiol. 2015 Apr 28. [Epub ahead of print]

PMID:
25916737
6.

Organ-Specific Cancer Metabolism and Its Potential for Therapy.

Elia I, Schmieder R, Christen S, Fendt SM.

Handb Exp Pharmacol. 2015 Apr 26. [Epub ahead of print]

PMID:
25912014
7.

[Cardiac effects of hypertension].

Schmieder RE, Nitschmann S.

Internist (Berl). 2015 May;56(5):583-5. doi: 10.1007/s00108-015-3694-z. German. No abstract available.

PMID:
25874737
8.

Low resting heart rates are associated with new-onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies.

Böhm M, Schumacher H, Linz D, Reil JC, Ukena C, Lonn E, Teo K, Sliwa K, Schmieder RE, Sleight P, Yusuf S.

J Intern Med. 2015 Apr 15. doi: 10.1111/joim.12373. [Epub ahead of print]

PMID:
25872921
9.

Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.

Schmieder RE, Mitrovic V, Hengstenberg C.

Clin Res Cardiol. 2015 Mar 19. [Epub ahead of print]

PMID:
25787721
10.

New approaches in the treatment of hypertension.

Oparil S, Schmieder RE.

Circ Res. 2015 Mar 13;116(6):1074-95. doi: 10.1161/CIRCRESAHA.116.303603.

PMID:
25767291
11.

[Renal denervation in refractory hypertension: joint statement of the German hypertension league DHL eV and the German societies of cardiology, angiology, nephrology and radiology].

Vonend O, Böhm M, Eckert S, Hausberg M, Rittger H, Rump LC, Schmieder R, Schulte KL, Schunkert H, Uder M, Veelken R, Vorwerk D, Weil J, Wenzel U, Mahfoud F.

Dtsch Med Wochenschr. 2015 Mar;140(5):363. doi: 10.1055/s-0041-100835. Epub 2015 Mar 3. German.

PMID:
25734680
12.

Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension.

Pöss J, Ewen S, Schmieder RE, Muhler S, Vonend O, Ott C, Linz D, Geisel J, Rump LC, Schlaich M, Böhm M, Mahfoud F.

Clin Res Cardiol. 2015 Feb 26. [Epub ahead of print]

PMID:
25715938
13.

First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.

Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G; GSR Investigators.

Hypertension. 2015 Apr;65(4):766-74. doi: 10.1161/HYPERTENSIONAHA.114.05010. Epub 2015 Feb 17.

PMID:
25691618
14.

Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.

Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E, van der Giet M, Hoyer J, Furniss SS, Foran JP, Witkowski A, Januszewicz A, Schoors D, Tsioufis K, Rensing BJ, Scott B, Ng GA, Ott C, Schmieder RE; ROX CONTROL HTN Investigators.

Lancet. 2015 Apr 25;385(9978):1634-41. doi: 10.1016/S0140-6736(14)62053-5. Epub 2015 Jan 23. Erratum in: Lancet. 2015 Apr 25;385(9978):1622.

PMID:
25620016
15.

Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.

Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Ferreira AC, Pieper A, Kimmeskamp-Kirschbaum N, Bakris GL.

Am J Nephrol. 2014;40(6):572-81. doi: 10.1159/000371497. Epub 2015 Jan 10.

PMID:
25591469
16.

Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.

Böhm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O'Donnell M, Yusuf S.

Hypertension. 2015 Mar;65(3):651-61. doi: 10.1161/HYPERTENSIONAHA.114.04568. Epub 2015 Jan 12.

PMID:
25583157
17.

Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice.

Bramlage P, Fronk EM, Wolf WP, Smolnik R, Sutton G, Schmieder RE.

Vasc Health Risk Manag. 2014 Dec 17;11:1-8. doi: 10.2147/VHRM.S75380. eCollection 2015.

18.

Wilder's principle: pre-treatment value determines post-treatment response.

Messerli FH, Bangalore S, Schmieder RE.

Eur Heart J. 2015 Mar 1;36(9):576-9. doi: 10.1093/eurheartj/ehu467. Epub 2014 Dec 23. Review. No abstract available.

PMID:
25540187
19.

Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome.

Raff U, Walker S, Ott C, Schneider MP, Schmieder RE.

J Clin Hypertens (Greenwich). 2015 Feb;17(2):98-104. doi: 10.1111/jch.12458. Epub 2014 Dec 24.

PMID:
25537177
20.

Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies.

Böhm M, Schumacher H, Schmieder RE, Mann JF, Teo K, Lonn E, Sleight P, Mancia G, Linz D, Mahfoud F, Ukena C, Sliwa K, Bakris G, Yusuf S.

J Intern Med. 2014 Nov 27. doi: 10.1111/joim.12333. [Epub ahead of print]

PMID:
25431275
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk